We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

5 hedge funds and large institutions have $2.49M invested in Hepion Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding

Funds holding: 4 → 5 (+1)

9% less capital invested

Capital invested by funds: $2.75M → $2.49M (-$255K)

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$569K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$284K

Top Sellers

Rank Fund Capital Flow
1
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$8K
2
MCIA
Mountain Capital Investment Advisors
Colorado
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$1K – – –
Cambridge Investment Research Advisors
27
Cambridge Investment Research Advisors
Iowa
– -$8K – –
MCIA
28
Mountain Capital Investment Advisors
Colorado
– -$3K – –
1
2

HEPA Hedge Fund Activity: Q4 2017 in Review

5 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q4 2017, worth a combined $2.49M — down 9.3% from $2.75M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new HEPA positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $569K. The largest seller was Cambridge Investment Research Advisors, cutting an estimated $8K.

  • 5 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q4 2017, up from 4 in Q3 2017.
  • Funds reported $2.49M of Hepion Pharmaceuticals stock for Q4 2017, down 9.3% quarter-over-quarter.
  • 1 fund opened new Hepion Pharmaceuticals positions in Q4 2017 and 0 closed out, a net change of +1 holder.
  • The largest Hepion Pharmaceuticals buyer in Q4 2017 was Anson Funds Management, an estimated $569K added.
  • The largest Hepion Pharmaceuticals seller in Q4 2017 was Cambridge Investment Research Advisors, an estimated $8K sold.

Based on aggregated 13F filings for Q4 2017.